Literature DB >> 32925293

Retinopathy of Prematurity: How to Prevent the Third Epidemics in Developing Countries.

Rajvardhan Azad1, Claire Gilbert2, Anil B Gangwe3, Peiquan Zhao4, Wei-Chi Wu5,6, Puja Sarbajna7, Anand Vinekar7.   

Abstract

Retinopathy of prematurity (ROP) is vasoproliferative disease affecting preterm infants and is a leading cause of avoidable childhood blindness worldwide. The world is currently experiencing the third epidemic of ROP, where majority of the cases are from middle-income countries. Over 40% of the world's premature infants were born in India, China, Bangladesh, Pakistan, and Indonesia. Together with other neighboring nations, this region has unique challenges in ROP management. Key aspects of the challenges including heavier and more mature infants developing severe ROP. Current strategies include adoption of national screening guidelines, telemedicine, integrating vision rehabilitation and software innovations in the form of artificial intelligence. This review overviews some of these aspects.

Entities:  

Mesh:

Year:  2020        PMID: 32925293     DOI: 10.1097/APO.0000000000000313

Source DB:  PubMed          Journal:  Asia Pac J Ophthalmol (Phila)        ISSN: 2162-0989


  3 in total

1.  Frequency of retinopathy of prematurity (ROP) in infants screened for ROP: two years follow-up results of a single center in Turkey.

Authors:  Adem Ugurlu
Journal:  Biomedicine (Taipei)       Date:  2021-09-01

2.  ROP-like retinopathy in full/near-term newborns: A etiology, risk factors, clinical and genetic characteristics, prognosis and management.

Authors:  Limei Sun; Wenjia Yan; Li Huang; Songshan Li; Jia Liu; Yamei Lu; Manxiang Su; Zhan Li; Xiaoyan Ding
Journal:  Front Med (Lausanne)       Date:  2022-08-10

3.  Retinopathy of Prematurity: Advances in the Screening and Treatment of Retinopathy of Prematurity Using a Single Center Approach.

Authors:  Audina M Berrocal; Kenneth C Fan; Hasenin Al-Khersan; Catherin I Negron; Timothy Murray
Journal:  Am J Ophthalmol       Date:  2021-07-21       Impact factor: 5.258

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.